Kazia Therapeutics Announces the Filing of Provisional Patent for Novel Strategy, Supported by Preclinical Data, to Prevent Metastatic Recurrence in Triple-Negative Breast Cancer
Kazia Therapeutics filed a provisional patent for a strategy using its lead asset paxalisib to prevent metastatic recurrence in high-risk early-stage triple-negative breast cancer. Preclinical models showed adjuvant paxalisib reduced residual disease by 95% and lung metastatic burden by 40%, while ex vivo studies demonstrated complete disruption of circulating tumor cell clusters.
Key figures
- Ctc cluster disruption
- 100%
- Residual disease reduction
- 95%
- Metastatic burden reduction
- 40%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.